| Jeremy S Berg, DO | |
|
5430 Linton Blvd, Delray Beach, FL 33484-6512 | |
| (847) 386-7744 | |
| Not Available |
| Full Name | Jeremy S Berg |
|---|---|
| Gender | Male |
| Speciality | Critical Care (intensivists) |
| Experience | 24 Years |
| Location | 5430 Linton Blvd, Delray Beach, Florida |
| Accepts Medicare Assignments | May be. He may accept the Medicare-approved amount; you may be billed for more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1104095157 | NPI | - | NPPES |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Intensive Care Consortium Inc | 0244269413 | 370 |
News Archive
PharmAthene, Inc. a biodefense company developing medical countermeasures against biological and chemical threats, today announced that it has closed its previously announced registered public offering of 4,300,000 shares of its common stock at a price to the public of $3.50 per share.
Scientists want to make a chink in the armor of a bacterium that has little name recognition yet is the number-one bacterial cause of the diarrhea, vomiting and stomach pain Americans experience annually.
It's the late 1970s, and a man with an unexplained high hemoglobin level (Hb) is referred to Namsos Hospital north of Trondheim, Norway. It turns out that four members of his family have the same condition. Doctor Kjell Kanelønning is the physician who treats the family.
A new scientific discovery may provide a future avenue for treatment and prevention of Alzheimer's disease.
The U.S. Food and Drug Administration today approved Linzess (linaclotide) to treat chronic idiopathic constipation and to treat irritable bowel syndrome with constipation (IBS-C) in adults.
› Verified 1 days ago
| Entity Name | Intensive Care Consortium Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1629019062 PECOS PAC ID: 0244269413 Enrollment ID: O20050808000883 |
News Archive
PharmAthene, Inc. a biodefense company developing medical countermeasures against biological and chemical threats, today announced that it has closed its previously announced registered public offering of 4,300,000 shares of its common stock at a price to the public of $3.50 per share.
Scientists want to make a chink in the armor of a bacterium that has little name recognition yet is the number-one bacterial cause of the diarrhea, vomiting and stomach pain Americans experience annually.
It's the late 1970s, and a man with an unexplained high hemoglobin level (Hb) is referred to Namsos Hospital north of Trondheim, Norway. It turns out that four members of his family have the same condition. Doctor Kjell Kanelønning is the physician who treats the family.
A new scientific discovery may provide a future avenue for treatment and prevention of Alzheimer's disease.
The U.S. Food and Drug Administration today approved Linzess (linaclotide) to treat chronic idiopathic constipation and to treat irritable bowel syndrome with constipation (IBS-C) in adults.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jeremy S Berg, DO 172 E Schiller St, Elmhurst, IL 60126-2816 Ph: (630) 941-2638 | Jeremy S Berg, DO 5430 Linton Blvd, Delray Beach, FL 33484-6512 Ph: (847) 386-7744 |
News Archive
PharmAthene, Inc. a biodefense company developing medical countermeasures against biological and chemical threats, today announced that it has closed its previously announced registered public offering of 4,300,000 shares of its common stock at a price to the public of $3.50 per share.
Scientists want to make a chink in the armor of a bacterium that has little name recognition yet is the number-one bacterial cause of the diarrhea, vomiting and stomach pain Americans experience annually.
It's the late 1970s, and a man with an unexplained high hemoglobin level (Hb) is referred to Namsos Hospital north of Trondheim, Norway. It turns out that four members of his family have the same condition. Doctor Kjell Kanelønning is the physician who treats the family.
A new scientific discovery may provide a future avenue for treatment and prevention of Alzheimer's disease.
The U.S. Food and Drug Administration today approved Linzess (linaclotide) to treat chronic idiopathic constipation and to treat irritable bowel syndrome with constipation (IBS-C) in adults.
› Verified 1 days ago
Dr. Chelsea Chapkin Albanese, D.O. Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 15340 S Jog Rd Ste 200, Delray Beach, FL 33446 Phone: 561-496-7200 | |
Dr. Alvin Gordon Beyerlein Jr., MD Critical Care Medicine Medicare: Medicare Enrolled Practice Location: 15300 S Jog Rd Ste 205, Delray Beach, FL 33446 Phone: 561-493-7200 Fax: 561-496-7989 | |
Dr. Ahmet H Lavkan, MD Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 4662 Hammock Cir, Delray Beach, FL 33445 Phone: 561-254-6464 | |
Marlon Amos Labi, M.D. Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 13593 Barcelona Lake Cir, Delray Beach, FL 33446 Phone: 954-849-4953 | |
John Receveur, M.D. Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 2932 Sw 22nd Cir Apt B, Delray Beach, FL 33445 Phone: 302-507-4975 | |
Rodolfo Reyes, M.D. Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 601 N Congress Ave Ste 403, Delray Beach, FL 33445 Phone: 561-272-1618 Fax: 561-272-2880 | |
Marie Rubby Roger, M.D. Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 13455 S Military Trl Ste A, Delray Beach, FL 33484 Phone: 561-288-6153 Fax: 561-288-6087 |